Apitolisib (GDC-0980)

Apitolisib (GDC-0980) is an inhibitor of PI3K and IKK and related targets used in studies of PI3K-Akt-mTOR Signaling and NF-kB Signaling and related signaling programs. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to growth-factor signaling, survival control, and nutrient-sensing outputs and inflammatory transcriptional control and stress-responsive survival signaling in apoptosis, autophagy, and cancer models.

By inhibiting PI3K and IKK and related targets, Apitolisib (GDC-0980) can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs and inflammatory transcriptional control and stress-responsive survival signaling. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving PI3K and IKK and related targets
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling and NF-kB Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Apitolisib (GDC-0980) is appropriate when a defined chemical perturbant is needed to connect PI3K and IKK and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.